Tirzepatide is currently only available on the NHS in England and Wales via specialist weight management services, with a phased roll out to primary care settings in England including GPs
A recent study entitled Elevation of glutathione as a therapeutic strategy in Alzheimers disease concludes: Increasing glutathione remains a promising therapeutic strategy to slow or prevent MCI and Alzheimers disease. Considering that glutathione levels continue to decline as we age, and that both AD and MCI increase with age, supplementation with effective glutathione can play an important role in prevention, or slowing the progression of this disease
Wall BT, Stephens FB, Constantin-Teodosiu D, Marimuthu K, Macdonald IA, Greenhaff PL
[2] Treatment typically begins with a dose of 0.6 mg once daily, which is increased weekly in 0.6 mg increments until the maintenance dose of 3.0 mg is reached
We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them, Ed Cinca, senior vice president of marketing & patient solutions at Novo Nordisk said in the press release